Back to Search
Start Over
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe
- Source :
- The Lancet. Gastroenterology & Hepatology, Lancet Gastroenterol Hepatol, lancet. Gastroenterology & hepatology, 3(2), 125-133. Elsevier Limited, Marshall, A D, Cunningham, E B, Nielsen, S, Aghemo, A, Alho, H, Backmund, M, Bruggmann, P, Dalgard, O, Seguin-Devaux, C, Flisiak, R, Foster, G R, Gheorghe, L, Goldberg, D, Goulis, I, Hickman, M, Hoffmann, P, Jancorienė, L, Jarcuska, P, Kåberg, M, Kostrikis, L G, Makara, M, Maimets, M, Marinho, R T, Matičič, M, Norris, S, Ólafsson, S, Øvrehus, A, Pawlotsky, J-M, Pocock, J, Robaeys, G, Roncero, C, Simonova, M, Sperl, J, Tait, M, Tolmane, I, Tomaselli, S, van der Valk, M, Vince, A, Dore, G J, Lazarus, J V, Grebely, J & International Network on Hepatitis in Substance Users (INHSU) 2018, ' Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe ', The Lancet Gastroenterology & Hepatology, vol. 3, no. 2, pp. 125-133 . https://doi.org/10.1016/S2468-1253(17)30284-4, Marshall, A D, Cunningham, E B, Nielsen, S, Aghemo, A, Alho, H, Backmund, M, Bruggmann, P, Dalgard, O, Seguin-Devaux, C, Flisiak, R, Foster, G R, Gheorghe, L, Goldberg, D, Goulis, I, Hickman, M, Hoffmann, P, Jancorienė, L, Jarcuska, P, Kåberg, M, Kostrikis, L G, Makara, M, Maimets, M, Marinho, R T, Matičič, M, Norris, S, Ólafsson, S, Øvrehus, A, Pawlotsky, J-M, Pocock, J, Robaeys, G, Roncero, C, Simonova, M, Sperl, J, Tait, M, Tolmane, I, Tomaselli, S, van der Valk, M, Vince, A, Dore, G J, Lazarus, J V, Grebely, J 2018, ' Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe ', Lancet Gastroenterology and Hepatology, vol. 3, no. 2, pp. 125–133 . https://doi.org/10.1016/S2468-1253(17)30284-4
- Publication Year :
- 2018
- Publisher :
- Elsevier BV, 2018.
-
Abstract
- All-oral direct-acting antiviral drugs (DAAs) for hepatitis C virus, which have response rates of 95% or more, represent a major clinical advance. However, the high list price of DAAs has led many governments to restrict their reimbursement. We reviewed the availability of, and national criteria for, interferon-free DAA reimbursement among countries in the European Union and European Economic Area, and Switzerland. Reimbursement documentation was reviewed between Nov 18, 2016, and Aug 1, 2017. Primary outcomes were fibrosis stage, drug or alcohol use, prescriber type, and HIV co-infection restrictions. Among the 35 European countries and jurisdictions included, the most commonly reimbursed DAA was ombitasvir, paritaprevir, and ritonavir, with dasabuvir, and with or without ribavirin (33 [94%] countries and jurisdictions). 16 (46%) countries and jurisdictions required patients to have fibrosis at stage F2 or higher, 29 (83%) had no listed restrictions based on drug or alcohol use, 33 (94%) required a specialist prescriber, and 34 (97%) had no additional restrictions for people co-infected with HIV and hepatitis C virus. These findings have implications for meeting WHO targets, with evidence of some countries not following the 2016 hepatitis C virus treatment guidelines by the European Association for the Study of Liver. 3 2 125 133
- Subjects :
- hepatitis C virus
HIV Infections
chemistry.chemical_compound
0302 clinical medicine
Antiviral Agents/economics
HIV-HCV co-infection
030212 general & internal medicine
Reimbursement
liver fibrosis
media_common
Dasabuvir
Coinfection
Health Policy
Gastroenterology
Hepatitis C
3. Good health
Europe
Hepatitis C, Chronic/complications
Insurance, Health, Reimbursement
030211 gastroenterology & hepatology
Switzerland
medicine.drug
medicine.medical_specialty
HIV Infections/complications
Antiviral Agents
Drug Costs
03 medical and health sciences
hepatitis C treatment
medicine
Humans
media_common.cataloged_instance
European Union
European union
PWID
Intensive care medicine
Hepatitis
direct-acting antiviral
Hepatology
business.industry
Hepatitis C, Chronic
alcohol use
medicine.disease
reimbursement
Virology
Ombitasvir
chemistry
Paritaprevir
Ritonavir
business
treatment restrictions
Subjects
Details
- ISSN :
- 24681253
- Volume :
- 3
- Database :
- OpenAIRE
- Journal :
- The Lancet Gastroenterology & Hepatology
- Accession number :
- edsair.doi.dedup.....14bff15ad21c3e93fdf786915d0ce23a